DOCSLIB.ORG

Test Updates

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Test Updates Effective Date: Monday, October 10, 2016 Test Updates In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, October 10, 2016 Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Discontinued Tests - Tests being discontinued with alternate testing suggestions. Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases. If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes. The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document. NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 1 of 24 Effective Date: Monday, October 10, 2016 Test Updates Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments DUID/DRE Expanded Drug Screen Add- 8075U • On, Urine (Forensic) DUID/DRE Panel, Blood (Forensic) 10010B • (CSA) - IN State Tox Lab DUID/DRE Panel, Blood (Forensic) 10024B • (CSA) - IN State Tox Lab DUID/DRE Panel, Blood (Forensic) 10041B • (CSA) - NC SCL DUID/DRE Panel, Urine (Forensic) (CSA) 10010U • - IN State Tox Lab DUID/DRE Panel, Urine (Forensic) (CSA) 10024U • - IN State Tox Lab 8098B Drug Screen (GC/MS), Blood • 8098U Drug Screen (GC/MS), Urine • 1876B Drug Screen - Expanded, Blood • 1876FL Drug Screen - Expanded, Fluid • 1876SP Drug Screen - Expanded, Serum/Plasma • 1876U Drug Screen - Expanded, Urine • Drug-Facilitated Sexual Assault Screen, 1450SP • Serum/Plasma (Forensic) Drug-Facilitated Sexual Assault Survey 2, 1452B • Blood (Forensic) Drug-Facilitated Sexual Assault Survey 2, 1452U • Urine (Forensic) GC/MS Drug Screen (Acid/Neutral), 1860B • Blood (Forensic) Postmortem Toxicology - SIDS Screen, 4177TI • Tissue (Forensic) Postmortem Toxicology - SIDS Screen, 4177U • Urine (Forensic) Postmortem, Basic to Expanded 8063B • Upgrade, Blood (Forensic) Postmortem, Basic to Expanded 8063FL • Upgrade, Fluid (Forensic) Postmortem, Basic to Expanded 8063SP • Upgrade, Serum/Plasma (Forensic) Postmortem, Basic to Expanded 8063TI • Upgrade, Tissue (Forensic) Postmortem, Basic to Expanded 8063U • Upgrade, Urine (Forensic) Postmortem, Basic w/Vitreous Alcohol 8041B • Confirmation, Blood (Forensic) Postmortem, Basic w/o Alcohol, Blood 8061B • (Forensic) 8061TI Postmortem, Basic w/o Alcohol, Tissue • Postmortem, Basic w/o Alcohol, Urine 8061U • (Forensic) NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 2 of 24 Effective Date: Monday, October 10, 2016 Test Updates Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments 8051B Postmortem, Basic, Blood (Forensic) • 8051FL Postmortem, Basic, Fluid (Forensic) • Postmortem, Basic, Serum/Plasma 8051SP • (Forensic) 8051TI Postmortem, Basic, Tissue (Forensic) • 8051U Postmortem, Basic, Urine (Forensic) • Postmortem, Expanded w/Vitreous 8042B • Alcohol Confirmation, Blood (Forensic) Postmortem, Expanded w/Vitreous 10052B Alcohol Confirmation, Blood (Forensic) • (CSA) Postmortem, Expanded w/Vitreous 8057B Alcohol Confirmation, Blood - University • of MI (CSA) Postmortem, Expanded w/o Alcohol, 8062B • Blood (Forensic) Postmortem, Expanded w/o Alcohol, 8062U • Urine (Forensic) 8052B Postmortem, Expanded, Blood (Forensic) • 8052FL Postmortem, Expanded, Fluid (Forensic) • Postmortem, Expanded, Serum/Plasma 8052SP • (Forensic) Postmortem, Expanded, Tissue 8052TI • (Forensic) 8052U Postmortem, Expanded, Urine (Forensic) • Postmortem, Expert w/Vitreous Alcohol 8043B • Confirmation, Blood (Forensic) Postmortem, Expert w/Vitreous Alcohol 10092B • Confirmation, Blood (Forensic) (CSA) Postmortem, Expert w/Vitreous Alcohol 10151B • Confirmation, Blood (Forensic) (CSA) 8092B Postmortem, Expert, Blood (Forensic) • 8092FL Postmortem, Expert, Fluid (Forensic) • Postmortem, Expert, Serum/Plasma 8092SP • (Forensic) 8092TI Postmortem, Expert, Tissue (Forensic) • 8092U Postmortem, Expert, Urine (Forensic) • Postmortem, SIDS Screen, Blood 4177B • (Forensic) NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 3 of 24 Effective Date: Monday, October 10, 2016 Test Updates Test Changes 8075U DUID/DRE Expanded Drug Screen Add-On, Urine (Forensic) Summary of Changes: Scope of Analysis was changed. Order of Reporting was changed. Didesmethylsibutramine, Loxapine, Sibutramine and Tranylcypromine were removed. Scope of Analysis: LC/TOF-MS (80304): 2C-B, 2C-E, 5-MeO-DALT, 7-Amino Flunitrazepam, 9- Method (CPT Code) Hydroxyrisperidone, 10-Hydroxycarbazepine, Alfentanil, Amitriptyline, Amoxapine, Atomoxetine, Atropine, Benztropine, Bromo-Dragon FLY, Brompheniramine, Bupivacaine, Buprenorphine, Bupropion, Buspirone, Butorphanol, BZP, Caffeine, Carbamazepine, Carbamazepine-10,11-Epoxide, Carisoprodol, Chlorpheniramine, Chlorpromazine, Citalopram / Escitalopram, Clomipramine, Clonidine, Clozapine, Cotinine, Cyclobenzaprine, Desipramine, Desmethylclomipramine, Desmethyldoxepin, Desmethyltrimipramine, Dextro / Levo Methorphan, Dextrorphan / Levorphanol, Dicyclomine, Diltiazem, Diphenhydramine, Donepezil, Doxepin, Doxylamine, Eszopiclone / Zopiclone, Fentanyl, Flecainide, Flunitrazepam, Fluoxetine, Fluvoxamine, Guaifenesin, Hydroxybupropion, Hydroxyzine, Imipramine, Ketamine, Lacosamide, Lamotrigine, Levamisole, Levetiracetam, Lidocaine, LSD, Maprotiline, mCPP, MDMA, MDPV, Memantine, Meperidine, Mephedrone, Mepivacaine, Meprobamate, Mescaline, Mesoridazine, Metaxalone, Methaqualone, Methcathinone, Methedrone, Methocarbamol, Methylone, Methylphenidate, Mexiletine, Mirtazapine, Mitragynine, Monoethylglycinexylidide (MEGX), Nalbuphine, Naloxone, Nicotine, Norbuprenorphine - Total, Norclozapine, Norfentanyl, Norflunitrazepam, Norfluoxetine, Norketamine, Normeperidine, Nortriptyline, O- Desmethyltramadol, O-Desmethylvenlafaxine, Olanzapine, Orphenadrine, Papaverine, Paroxetine, Pentazocine, Phenazepam, Pheniramine, Phensuximide, Phenyltoloxamine, Phenytoin, PMA, Primidone, Procainamide, Promazine, Promethazine, Protriptyline, Psilocin, Pyrilamine, Quetiapine, Quinidine, Quinine, Ramelteon, Risperidone, Salvinorin B, Sertraline, Sildenafil, Sufentanil, Tapentadol, Tetrahydrozoline, TFMPP, Theophylline, Thioridazine, Thiothixene, Tiletamine, Topiramate, Tramadol, Trazodone, Trihexyphenidyl, Trimipramine, Triprolidine, Venlafaxine, Verapamil, Xylazine, Yohimbine, Zaleplon, Zolazepam, Zolpidem, Zonisamide, Scope Statement 10010B DUID/DRE Panel, Blood (Forensic) (CSA) - IN State Tox Lab Summary of Changes: Scope of Analysis was changed. Ephedrine, Pseudoephedrine and Norpseudoephedrine were added. Ephedrine / Pseudoephedrine and Norpseudoephedrine / Phenylpropanolamine were removed. Scope of Analysis: ELISA (80301): Cannabinoids, Barbiturates Method (CPT Code) LC/TOF-MS (80304): Morphine, Oxymorphone, Hydromorphone, Codeine, Oxycodone, Ephedrine, Pseudoephedrine, Norpseudoephedrine, 6- Monoacetylmorphine, Hydrocodone, Amphetamine, MDMA, Methamphetamine, Norfentanyl, Benzoylecgonine, Cocaine, 7-Amino Clonazepam, Zolpidem, Meprobamate, Fentanyl, Midazolam, Methadone, Clonazepam, Alpha- Hydroxyalprazolam, Carisoprodol, Lorazepam, Nordiazepam, Oxazepam, Diazepam, Alprazolam, Desalkylflurazepam, Temazepam NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 4 of 24 Effective Date: Monday, October 10, 2016 Test Updates Test Changes Compound Name Units Reference Comment Ephedrine ng/mL Pseudoephedrine ng/mL Norpseudoephedrine ng/mL 10024B DUID/DRE Panel, Blood (Forensic) (CSA) - IN State Tox Lab Summary of Changes: Scope of Analysis was changed. Ephedrine, Pseudoephedrine and Norpseudoephedrine were added. Ephedrine / Pseudoephedrine and Norpseudoephedrine / Phenylpropanolamine were removed. Scope of Analysis: ELISA (80301): Barbiturates Method (CPT Code) LC/TOF-MS (80304): Morphine, Oxymorphone, Hydromorphone, Codeine, Oxycodone, Ephedrine, Pseudoephedrine, Norpseudoephedrine, 6- Monoacetylmorphine, Hydrocodone, Amphetamine, MDMA, Methamphetamine, Norfentanyl, Benzoylecgonine, Cocaine, 7-Amino Clonazepam, Zolpidem, Meprobamate, Fentanyl, Midazolam, Methadone, Clonazepam, Alpha- Hydroxyalprazolam, Carisoprodol, Lorazepam, Nordiazepam, Oxazepam, Diazepam, Alprazolam, Desalkylflurazepam, Temazepam Compound Name Units Reference Comment Ephedrine ng/mL Pseudoephedrine ng/mL Norpseudoephedrine ng/mL 10041B DUID/DRE Panel, Blood (Forensic) (CSA) - NC SCL Summary of Changes: Scope of Analysis was changed. Order of Reporting was changed. Phendimetrazine and Phenmetrazine were removed. Scope of Analysis: ELISA (80301): Cannabinoids, Barbiturates Method (CPT Code) LC/TOF-MS (80304): 6-Monoacetylmorphine, 7-Amino Clonazepam, 7-Amino Flunitrazepam, 7-Amino Nitrazepam, Alpha-Hydroxyalprazolam, Alprazolam, Amitriptyline, Amphetamine, Benzoylecgonine, Bupropion, BZP, Carisoprodol, Chlordiazepoxide, Chlorpheniramine, Chlorpromazine, Citalopram / Escitalopram, Clobazam, Clomipramine, Clonazepam, Clozapine, Cocaethylene,
Load more

Recommended publications
  • Impact of CYP2C19 Genotype on Sertraline Exposure in 1200 Scandinavian Patients
    www.nature.com/npp ARTICLE Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients Line S. Bråten 1,2, Tore Haslemo1,2, Marin M. Jukic3,4, Magnus Ingelman-Sundberg 3, Espen Molden1,5 and Marianne K. Kringen1,2 Sertraline is an (SSRI-)antidepressant metabolized by the polymorphic CYP2C19 enzyme. The aim of this study was to investigate the impact of CYP2C19 genotype on the serum concentrations of sertraline in a large patient population. Second, the proportions of patients in the various CYP2C19 genotype-defined subgroups obtaining serum concentrations outside the therapeutic range of sertraline were assessed. A total of 2190 sertraline serum concentration measurements from 1202 patients were included retrospectively from the drug monitoring database at Diakonhjemmet Hospital in Oslo. The patients were divided into CYP2C19 genotype-predicted phenotype subgroups, i.e. normal (NMs), ultra rapid (UMs), intermediate (IMs), and poor metabolisers (PMs). The differences in dose-harmonized serum concentrations of sertraline and N-desmethylsertraline-to-sertraline metabolic ratio were compared between the subgroups, with CYP2C19 NMs set as reference. The patient proportions outside the therapeutic concentration range were also compared between the subgroups with NMs defined as reference. Compared with the CYP2C19 NMs, the sertraline serum concentration was increased 1.38-fold (95% CI 1.26–1.50) and 2.68-fold (95% CI 2.16–3.31) in CYP2C19 IMs and PMs, respectively (p < 0.001), while only a marginally lower serum concentration (−10%) was observed in CYP2C19 UMs (p = 0.012). The odds ratio for having a sertraline concentration above the therapeutic reference range was 1.97 (95% CI 1.21–3.21, p = 0.064) and 8.69 (95% CI 3.88–19.19, p < 0.001) higher for IMs and PMs vs.
    [Show full text]
  • ZOLOFT® 50 Mg and 100 Mg Tablets
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME ZOLOFT® 50 mg and 100 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 50 mg tablet contains sertraline hydrochloride equivalent to 50 mg sertraline. Each 100 mg tablet contains sertraline hydrochloride equivalent to 100 mg sertraline. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM ZOLOFT 50 mg tablets: white film-coated tablets marked with the Pfizer logo on one side and “ZLT” scoreline “50” on the other. Approximate tooling dimensions are 1.03 cm x 0.42 cm x 0.36 cm. ZOLOFT 100 mg tablets: white film-coated tablets marked with the Pfizer logo on one side and “ZLT-100” or “ZLT 100” on the other. Approximate tooling dimensions are 1.31 cm x 0.52 cm x 0.44 cm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Adults ZOLOFT is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. Following satisfactory response, continuation with ZOLOFT therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes. ZOLOFT is indicated for the treatment of obsessive compulsive disorder (OCD). Following initial response, sertraline has been associated with sustained efficacy, safety and tolerability in up 2 years of treatment of OCD. ZOLOFT is indicated for the treatment of panic disorder, with or without agoraphobia. ZOLOFT is indicated for the treatment of post-traumatic stress disorder (PTSD). ZOLOFT is indicated for the treatment of social phobia (social anxiety disorder).
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • (Mdma) in Non Conventional Matrices and Its Applications in Clinical Toxicology
    Doctoral Thesis Doctorat Farmacología Departament de Farmacología, de Terapéutica i de Toxicologia DISTRIBUTION OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) IN NON CONVENTIONAL MATRICES AND ITS APPLICATIONS IN CLINICAL TOXICOLOGY SIMONA PICHINI p Doctoral Thesis Doctorat Farmacología Departament de Farmacología, de Terapéutica i de Toxicologia DISTRIBUTION OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) IN NON CONVENTIONAL MATRICES AND ITS APPLICATIONS IN CLINICAL TOXICOLOGY Doctoral thesis submitted by Simona Pichini as a partial fulfillment of the requirements for the degree of Doctor by the Universitat Autònoma de Barcelona. The studies included in this thesis have been realized under the direction of Dr. Rafael de la Torre Fornell and Dr. Magí Farré Albaladejo at the Pharmacology Unit of the Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain; and at the Drug Research and Control Department of the Istituto Superiore di Sanità, Roma, Italy. Doctorate Program of the Universitat Autònoma de Barcelona. Signature of Thesis Director Signature of Thesis Director (Dr. Magí Farré Albaladejo) (Dr. Rafael de la Torre Fornell) Signature of Doctorand (Simona Pichini) Yo soy yo y aquéllos a quienes amo Jorge Bucay To my friends, treasure of my life Acknowledgements Acknowledgements A number of people contributed to high extent to achieve the objectives of this Doctoral Thesis prepared between the two cities of Rome and Barcelona. This means that there are many people I’d the opportunity to meet, to work with, to share wonderful and terrible moments, and that I’d like to thank in these pages. First of all, to Dr. Piergiorgio Zuccaro, my “creator”, who always believed in me, supported my job and hardly fought to give me all the possible opportunities to grow up as an investigator; To Dr.
    [Show full text]
  • Apo-Ropinirole
    New Zealand Data Sheet APO-ROPINIROLE 1. PRODUCT NAME APO-ROPINIROLE 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg and 5mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ropinirole hydrochloride 0.25mg Ropinirole hydrochloride 0.5mg Ropinirole hydrochloride 1mg Ropinirole hydrochloride 2mg Ropinirole hydrochloride 3mg Ropinirole hydrochloride 4mg Ropinirole hydrochloride 5mg Excipient(s) with known effect Contains lactose. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM APO-ROPINIROLE is available as oral, film coated tablets in the following strengths: APO-ROPINIROLE 0.25mg tablets are white, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “.25” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 0.5mg tablets are yellow, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “.5” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 1mg tablets are green, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “1” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 2mg tablets are pink, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “2” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 3mg tablets are purple, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “3” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 4mg tablets are pale brown, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “4” on one side and “APO’ on the other side.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Levomilnacipran for the Treatment of Major Depressive Disorder
    Out of the Pipeline Levomilnacipran for the treatment of major depressive disorder Matthew Macaluso, DO, Hala Kazanchi, MD, and Vikram Malhotra, MD An SNRI with n July 2013, the FDA approved levomil- Table 1 once-daily dosing, nacipran for the treatment of major de- Levomilnacipran: Fast facts levomilnacipran pressive disorder (MDD) in adults.1 It is I Brand name: Fetzima decreased core available in a once-daily, extended-release formulation (Table 1).1 The drug is the fifth Class: Serotonin-norepinephrine reuptake symptoms of inhibitor serotonin-norepinephrine reuptake inhibi- MDD and was well Indication: Treatment of major depressive tor (SNRI) to be sold in the United States disorder in adults tolerated in clinical and the fourth to receive FDA approval for FDA approval date: July 26, 2013 trials treating MDD. Availability date: Fourth quarter of 2013 Levomilnacipran is believed to be the Manufacturer: Forest Pharmaceuticals more active enantiomer of milnacipran, Dosage forms: Extended–release capsules in which has been available in Europe for 20 mg, 40 mg, 80 mg, and 120 mg strengths years and was approved by the FDA in Recommended dosage: 40 mg to 120 mg 2009 for treating fibromyalgia. Efficacy of capsule once daily with or without food levomilnacipran for treating patients with Source: Reference 1 MDD was established in three 8-week ran- domized controlled trials (RCTs).1 cial and occupational functioning in addi- Clinical implications tion to improvement in the core symptoms Levomilnacipran is indicated for treating of depression.5
    [Show full text]
  • Abecarnil/Allobarbital 959 Pharmacopoeias
    Abecarnil/Allobarbital 959 Pharmacopoeias. In Eur. (see p.vii). acamprosate’s action including inhibition of neuronal hyper- maleate in the treatment of anxiety disorders, hiccups, and nau- Ph. Eur. 6.2 (Acamprosate Calcium). A white or almost white excitability by antagonising excitatory amino acids such as sea and vomiting. Acepromazine, as the base, has also been giv- powder. Freely soluble in water; practically insoluble in alcohol glutamate. en in preparations for the management of insomnia. and in dichloromethane. A 5% solution in water has a pH of 5.5 1. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacol- Preparations to 7.0. ogy and clinical potential in the management of alcohol depend- ence after detoxification. Drugs 1997; 53: 1038–53. Proprietary Preparations (details are given in Part 3) Adverse Effects 2. Anonymous. Acamprosate for alcohol dependence? Drug Ther Denm.: Plegicil; Turk.: Plegicil. The main adverse effect of acamprosate is dosage-related diar- Bull 1997; 35: 70–2. Multi-ingredient: Fr.: Noctran. rhoea; nausea, vomiting, and abdominal pain occur less frequent- 3. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001; 62 (suppl ly. Other adverse effects have included pruritus, and occasionally 20): 42–8. a maculopapular rash; bullous skin reactions have occurred rare- 4. Overman GP, et al. Acamprosate for the adjunctive treatment of Aceprometazine (rINN) ly. Depression and fluctuations in libido have also been reported. alcohol dependence. Ann Pharmacother 2003; 37: 1090–9. Hypersensitivity reactions including urticaria, angioedema, and 5. Anton RF, et al. Combined pharmacotherapies and behavioral 16-64 CB; Aceprometazina; Acéprométazine; Aceprometazi- anaphylaxis have been reported very rarely.
    [Show full text]
  • Smumedical Journal
    SMU Medical Journal ISSN : 2349 – 1604 (Volume – 4, No. 1, January 2017) Review Article Indexed in SIS (USA), ASI (Germany), I2OR & i-Scholar (India), SJIF (Morocco) and Cosmos Foundation (Germany) databases. Impact Factor: 3.835 (SJIF) Analytical Aspects with Brief Overview of Depressants Sandeep Kumar1 Nand Gopal Giri2 Ashok Kumar Jaiswal3* Anil Kumar Jaiswal4 1M.Sc. (Forensic Science), LNJN NICFS, New Delhi 110085, 2Assistant Professor, Department of Chemistry, Shivaji College (University of Delhi) Raja Garden, New Delhi 110 027, 3Dept. of Forensic Medicine and toxicology, All India institute of Medical Sciences, New Delhi 110 029.4Assistant Professor, Department of Mathematics, St. Andrew’s PG College, Gorakhpur, UP. *Corresponding author Manuscript received : 30.10.2016 Manuscript accepted: 21.11.2016 Abstract Depressants are drugs that slow down the functions of the central nervous system (CNS). These drugs are used to reduce anxiety and insomnia without drowsiness. The depressants cause relaxed feeling if used in small quantity but cause unconsciousness, vomiting and even death if taken in high quantity. It affects concentration and coordination of a person by slowing down his/ her ability to respond in unexpected situations. These drugs are also attributed for their physiological and psychological effects, eventually in large dose it become lethal. The different 142 SMU Medical Journal, Volume – 4, No. – 1, January, 2017 physical and chemical features of some very often used depressants are discussed in this manuscript. Keyword: Depressant, TLC, UV spectroscopy, HPLC, GLC etc. Introduction The classical depressants are hypnotics (which induce sleep), most antianxiety medicine (diazepam or valium), muscle spasm prevent seizure, but these drugs rapidly develop dependence and tolerance which finally leads to coma and death, so use of these drugs is highly unsafe.
    [Show full text]